Bristol Confident To Move Deucravacitinib Into Phase III Lupus Trial

 
• By Jessica Merrill
  
Lupus Ribbon
Bristol Myers is moving its TYK2 inhibitor into Phase III in lupus • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D